Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.

Jayesh Desai,Hui K. Gan,Catherine Barrow,Michael B. Jameson,Victoria Atkinson,Andrew Haydon,Michael Millward,Stephen Begbie,Michael P. Brown,Ben Markman,William Patterson,Andrew G. Hill,Lisa G. Horvath,Adnan Nagrial,Gary Edward Richardson,Christopher Jackson,Michael Friedlander,Phillip Parente,Ben Tran,Lai Wang,Yunxin Chen,Zhiyu Tang,Wendy Huang,John Wu,Dewan Zeng,Lusong Luo,Benjamin Solomon

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.

2020

PURPOSELifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated t...

Keywords:

Pathology
Cancer research
dose escalation
Medicine
Kinase
open label
Oncology
Internal medicine
in patient

Correction
Source
Cite
Save

References

Citations